Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Open Access
- 29 November 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (23), 6497-6508
- https://doi.org/10.1158/1078-0432.ccr-12-2189
Abstract
Purpose: Long peptides are efficiently presented to both CD4+ and CD8+ T cells after intracellular processing by antigen-presenting cells. To investigate the safety and in vivo immunogenicity of synthetic overlapping long peptides (OLP) from a human tumor self-antigen, we conducted a phase I clinical trial with OLP from cancer-testis antigen NY-ESO-1 in various adjuvant combinations.Keywords
Other Versions
This publication has 29 references indexed in Scilit:
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patientsProceedings of the National Academy of Sciences of the United States of America, 2012
- Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humansThe Journal of Experimental Medicine, 2011
- The Present and Future of Peptide Vaccines for CancerThe Cancer Journal, 2011
- Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer PatientsClinical Cancer Research, 2011
- Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2011
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitProceedings of the National Academy of Sciences of the United States of America, 2008
- Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingProceedings of the National Academy of Sciences of the United States of America, 2008
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-primingProceedings of the National Academy of Sciences of the United States of America, 2007
- Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsProceedings of the National Academy of Sciences of the United States of America, 2006